Researchers at the University of Georgia and Sanofi Pasteur, the vaccines division of Sanofi, announced today the development of a vaccine that protects against multiple strains of both seasonal and pandemic H1N1 influenza in mouse models.
They published their findings recently in the Journal of Virology.
Researchers from UGA and Sanofi Pasteur, which has a research and development collaboration agreement with UGA, will present their data tomorrow, March 30, at the World Vaccine Congress US 2016 in Washington, D.C.
“One of the problems with current influenza vaccines is that we have to make predictions about which virus strains will be most prevalent every year and build our vaccines around those predictions,” said Ted Ross, director of UGA’s Center for Vaccines and Immunology and Georgia Research Alliance Eminent Scholar in Infectious Diseases in the College of Veterinary Medicine. “What we have developed is a vaccine that protects against multiple different strains of H1N1 virus at once, so we might be able to one day replace the current standard of care with this more broadly cross-protective vaccine.”
The H1N1 influenza virus caused a worldwide pandemic in 2009. When it was first detected, it was called swine flu because the virus was similar to those found in pigs, but the virus now circulates as a seasonal form of influenza.
Using a technique called Computationally Optimized Broadly Reactive Antigen, or COBRA, UGA researchers Donald Carter, Christopher Darby and Bradford Lefoley, along with Ross, created nine prototype synthetic compound vaccines constructed using genetic sequences from multiple influenza virus strains.
The COBRA vaccines were designed to recognize H1N1 viruses isolated within the last 100 years, but many of the experimental vaccines produced immunity against influenza strains not included in the design. This means that scientists may be able to produce a vaccine that not only protects against recognized seasonal and pandemic influenza strains, but also strains that have yet to be discovered.
Because this vaccine is generated from the genetic sequences of multiple flu viruses, it may protect against many strains over several years, Ross said. That would also allow for year-round manufacturing of the vaccine, since scientists would not have to halt production every year to identify the most prevalent strains.
This research is part of a broader effort to create a universal influenza vaccine, which would protect against all strains of the virus.
“We still have some work to do before we get a truly universal flu vaccine,” Ross said. “But the COBRA vaccine we’ve developed for H1N1 virus subtypes is a major step in the right direction.”
The Latest on: Flu vaccine
via Google News
The Latest on: Flu vaccine
- Chicago officials urge flu vaccine before peak seasonon December 1, 2019 at 7:22 am
CHICAGO — Health officials in Chicago say it’s not too late to get a flu shot. The Chicago Department of Public Health is hosting four flu clinics this week, offering free vaccines. The events are on ...
- Newcastle flu vaccine mix-up leaves children unprotectedon December 1, 2019 at 6:04 am
Hundreds of schoolchildren across Newcastle have missed out on the flu vaccine after a mix-up with consent forms. One school was told the day before its pupils were due to be vaccinated that more than ...
- Building a better flu vaccine -- one you don't have to get every yearon November 30, 2019 at 3:12 am
CNN — On June 24 at 11:34 AM, Michael Sonn became a part of medical history. That's the day Sonn became one of the first people to receive an experimental flu vaccine that could one day radically ...
- An experimental flu vaccine could radically change the shot you get every yearon November 29, 2019 at 9:54 am
At 11:34 a.m. June 24, Michael Sonn became a part of medical history.That's when Sonn became one of the first people to receive an experimental flu vaccine that could one day radically change the shot ...
- Global Influenza Diagnostics Market may see a growth rate of 6.86% and would reach the Market size of USD923.14 Million by 2024on November 29, 2019 at 3:33 am
Nov 29, 2019 (HTF Market Intelligence via COMTEX) -- This intelligence report provides a comprehensive analysis of the "Global Influenza Diagnostics Market. This includes Investigation of past ...
- Respiratory syncytial, parainfluenza and influenza virus infection in young children with acute lower respiratory infection in rural Gambiaon November 29, 2019 at 2:44 am
Naso- and oropharyngeal swabs were collected. Each month from February through December 2015, specimens from 50 children aged 2–23 months were randomly selected to test for respiratory syncytial (RSV) ...
- Health Watch: Flu vaccine less effective for overweight, obese patientson November 29, 2019 at 1:02 am
Metabolic changes, as people become overweight, affect many cells, including those in the immune system. The same problem also affects older patients. Developing a next-generation flu vaccine is a new ...
- How the flu vaccine is made each year to keep up with constantly mutating versions of the viruson November 28, 2019 at 5:00 am
The most common method uses eggs, as was done when the flu vaccine was first developed about eight decades ago. The viruses are injected into fertilized hen eggs and allowed to incubate for several ...
- Disrupting the Conserved Salt Bridge in the Trimerization of Influenza A Nucleoproteinon November 27, 2019 at 8:54 am
Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...
- An ‘unusual’ start to flu season: Influenza B predominates earlyon November 27, 2019 at 3:04 am
The proportion of outpatient visits attributed to influenza-like illness climbed above the national baseline for the first time this season, comprising 2.5% of visits during the week ending Nov. 16, ...
via Bing News